Breaking Finance News

A statement released earlier today by H.C. Wainwright about Aethlon Medical (UNKNOWN:AEMD) ups the target price to $3.00

Boasting a price of $1.05, Aethlon Medical (UNKNOWN:AEMD) traded 0.00% even on the day. With the last close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has increased 0.01% over the date range. Aethlon Medical has recorded a 50-day average of $0.00 and a two hundred day average of $0.00. Volume of trade held steady, with 0 shares of AEMD changing hands on par with the typical 0

In a report announced on 11/20/2017 H.C. Wainwright raised the target price of Aethlon Medical (UNKNOWN:AEMD) to $3.00 stating a potential upside of 1.86%.

Recent Performance Chart

Aethlon Medical (UNKNOWN:AEMD)

Aethlon Medical has 52 week low of $0.00 and a 52 week high of $0.00 and has a market capitalization of $0.

Brief Synopsis On Aethlon Medical (UNKNOWN:AEMD)

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *